The Column Group — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Santa Monica, US
Michael Einziger(Executive Officer, Director)Edna Coryell(Executive Officer, Director)Katherine Power(Director)Jessica Goldin(Executive Officer, Director)
BoardAnn Marie Simpson(Director)
Co-investors8VCDroia VenturesFrazier Life SciencesNovartis Venture FundRTW Investments L.P.Thuja Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.